| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4027 | pcm126 | Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low |
|
| DCC4028 | p-come 102 | Highly selective α1L adrenaline receptor agonist |
|
| DCC4029 | Pcpma-(1r,2r)-22e | Novel potent dopamine D3R agonist (Ki=4.1nM) |
|
| DCC4030 | Pcpma-(1r,2r)-30q | Novel potent and selective dopamine D3R partial agonist |
|
| DCC4031 | Pcpma-(1s,2s)-22e | Novel potent dopamine D3R antagonist |
|
| DCC4032 | Pcsk9 Modulator | Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9) |
|
| DCC4033 | Pcsk9-in-4d | Novel PCSK9 mRNA translation inhibitor |
|
| DCC4034 | Pcsk9-in-4g | Novel PCSK9 mRNA translation inhibitor |
|
| DCC4035 | Pcsk9-in-8b | Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
|
| DCC4036 | Pd-1 Inhibitor 16 | Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent |
|
| DCC4037 | Pd-1/pd-l1 Antagonist D2 | Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs |
|
| DCC4038 | Pd-1/pd-l1 Inhibitor 17 | Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity |
|
| DCC4039 | Pd-1/pd-l1 Inhibitor A30 | Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction |
|
| DCC4040 | Pd-1/pd-l1 Inhibitor Ch1 | Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized |
|
| DCC4041 | Pd-1/pd-l1 Inhibitor P18 | Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM) |
|
| DCC4042 | Pd-128907 Hydrochloride | Selective D3 dopamine receptor agonist |
|
| DCC4043 | Pd-151242 | Selective antagonist for human ETA receptors |
|
| DCC4044 | Pd160170 | Neuropeptide Y Y1 receptor antagonist |
|
| DCC4045 | Pd-160725 Isethionate | AMPA receptor antagonist |
|
| DCC4046 | Pd-161989 Isethionate | AMPA receptor antagonist |
|
| DCC4047 | Pd-174494 | Novel, potent, and selective NR1/2B NMDA receptor antagonist |
|
| DCC4048 | P-d1ago | Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors |
|
| DCC4049 | Pd26-tl07 | Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231) |
|
| DCC4050 | pda-66 | Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells |
|
| DCC4051 | Pdd4091 | Novel G6PD inhibitor |
|
| DCC4052 | Pde5-in-42 | Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor |
|
| DCC4053 | Pde7 Inhibitor S14 | Novel cell-permeable PDE7 inhibitor, targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model |
|
| DCC4054 | Pde9-in-16 | Novel selective PDE9 inhibitor with strong antioxidant activity, inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease |
|
| DCC4055 | Pde9-in-2 | Novel Potent, Selective, and Orally Bioavailable Inhibitor against Phosphodiesterase-9 (PDE9) |
|
| DCC4056 | P-decylaminophenol | Novel inhibitor of melanogenesis |
|
